Targeting gut microbiota in obesity: effects of prebiotics and probiotics

Nathalie M. Delzenne, Audrey M. Neyrinck, Fredrik Bäckhed and Patrice D. Cani

Abstract | At birth, the human colon is rapidly colonized by gut microbes. Owing to their vast number and their capacity to ferment nutrients and secrete bioactive compounds, these gastrointestinal microbes act as an environmental factor that affects the host’s physiology and metabolism, particularly in the context of obesity and its related metabolic disorders. Experiments that compared germ-free and colonized mice or analyzed the influence of nutrients that qualitatively change the composition of the gut microbiota (namely prebiotics) showed that gut microbes induce a wide variety of host responses within the intestinal mucosa and thereby control the gut’s barrier and endocrine functions. Gut microbes also influence the metabolism of cells in tissues outside of the intestines (in the liver and adipose tissue) and thereby modulate lipid and glucose homeostasis, as well as systemic inflammation, in the host. A number of studies describe characteristic differences between the composition and/or activity of the gut microbiota of lean individuals and those with obesity. Although these data are controversial, they suggest that specific phyla, classes or species of bacteria, or bacterial metabolic activities could be beneficial or detrimental to patients with obesity. The gut microbiota is, therefore, a potential nutritional and pharmacological target in the management of obesity and obesity-related disorders.

Introduction

The human gut is home to $10^{13}$ bacteria, which outnumber the total of eukaryotic cells in the human body by an order of magnitude. At birth, the gut of a neonate is sterile. However, at birth, it is immediately colonized by maternal and environmental bacteria, and the complexity of the resulting gut microbiota increases until the weaning to solid foods. The adult microbiota harbors 1,000–1,150 bacterial species, and some experts have suggested that 160 of these species constitute the core microbiota that is present in most individuals. Although many of these species are found in the majority of people, their relative abundance can vary greatly. By contrast, studies of microbial coding sequences (called the metagenome) have made it increasingly clear that the functions encoded by the metagenome exhibit great similarity between individuals. The human and mouse gut is dominated by several bacterial phyla including Bacteroidetes, Firmicutes and Actinobacteria.

Some studies have indicated that an altered gut microbiota is associated with several diseases that are particularly prevalent in the 21st century. For example, reduced microbial diversity—a sign of a dysfunctional ecosystem that leads to a decreased stability of the microbiota—has been associated with both inflammatory bowel disease and obesity. The first studies on the relationship between the composition of the gut microbiota and obesity have shown that the number of Firmicutes was increased whereas the number of Bacteroidetes was reduced in obese mice and humans compared with lean individuals. Interestingly, weight loss achieved by dieting was able to reverse those changes. Although the decrease in the number of Bacteroidetes was not observed in all studies, changes in this phylum have been suggested to result from an increased energy intake rather than being caused directly by obesity. The bacterial changes at the taxonomic level in individuals with obesity have been described elsewhere.

In the first part of this Review, we describe the major factors that could modulate gut microbiota composition, including genetic background, sex, age and diet of the host. In the second part, we describe how gut microbes change the energy metabolism of the host by altering the expression of genes involved in the development of adiposity and obesity-related metabolic disorders, including inflammation. The last part of the Review focuses on the potential role of specific nutrients that target the gut microbiota in the control of obesity and its comorbidities.

Selecting host-adapted gut microbiota

Various components influence the microbial ecology of the gut (Figure 1). In an elegant study, Rawls and coworkers demonstrated that the host can select an optimal microbiota. When germ-free zebrafish were colonized with anaerobic mouse gut microbiota and germ-free mice were colonized with aerobic zebrafish microbiota, the host microbiota reshaped the transplanted microbiota within 2 weeks in both cases. Obviously, physiological characteristics and habitats of fish and mice are very different. However, this observation suggests that the host...
The gut microbiota might modulate adiposity by changing the expression of host genes that are involved in fat storage and oxidation, gastrointestinal hormone production and barrier function and in the inflammatory response. Although all individuals are born with a specific microbiome, the diet can change both the composition and the activity of the microbiota. Certain fermentable carbohydrates with prebiotic properties can counteract the overexpression of several host targets that are involved in the development of adiposity, metabolic disorders and inflammation. 

The concept of prebiotics was proposed in 1995 on the basis of the observation that certain nondigestible carbohydrates, following fermentation by bacteria, can drive qualitative and selective changes in the composition of the gut microbiota, which have beneficial effects on the host’s health. The number of Bifidobacteria (phylum Actinobacteria) has been shown to increase in the presence of inulin-type fructans with prebiotic properties. This increase occurs within a few days, but rapidly disappears upon withdrawal of the prebiotic compounds (after 1 week). The extent of increase in the number of Bifidobacteria is also dependent on their initial number in the gut. Breastmilk also contains oligosaccharides with prebiotic properties that contribute to the increase in the number of Bifidobacteria after birth. These findings illustrate that diet has a crucial role in the modulation of the gut microbiota during an individual’s lifetime, and the nutrient composition of the diet has to be taken into account when studying the relationship between the composition of the gut microbiota and the host’s health.

The increased serum titers are required to maintain the gut microbiota. The gut microbiota is greatly responsive to dietary changes in adulthood, too. After switching mice to a high-fat Western diet, drastic changes occur in the composition of their gut microbiota. In particular, the number of bacteria that belong to the class Erysipelotrichi of the phylum Firmicutes increases dramatically. These responses are very rapid; they occur within the first 24 h after changing the animals’ diet. Dietary carbohydrates, especially those that are not digested in the upper part of the gut, might also change the composition of the gut microbiota.

Antibiotics exert a key influence on the composition of the gut microbiota, although the underlying mechanisms are yet to be clarified.

**Genetics**

Profiling the gut microbiota of eight different mouse strains—to mimic the genetic diversity of the human population—by DNA fingerprinting suggested that the genetic background of the host has a stronger influence on microbiota composition than the sex of the host. Another study confirmed that the genotype of the host is an important factor in selecting and shaping the gut microbiota. At birth, the sterile gut of the newborn baby is colonized by bacteria from the mother and the environment. Accordingly, the gut microbiota of both mice pups and human neonates closely resembles that of their mothers. As the mother and the offspring share half of their genes and part of their gut microbiota, whether the development of the gut microbiota is determined by the offspring’s genes or the offspring is supplied with an optimal gut microbiota at birth is unknown.

**Immune system**

The immune system also seems to be important in the selection of the gut microbiota. Mice that have abnormal Toll-like receptor (Tlr) signaling or produce bactericidal reactive oxygen species have elevated serum titers of antibodies against their commensal microbiota. The immune system also seems to be important in the selection of the gut microbiota. Mice that have abnormal Toll-like receptor (Tlr) signaling or produce bactericidal reactive oxygen species have elevated serum titers of antibodies against their commensal microbiota.

As mentioned previously, weaning to solid food has a profound effect on the composition and complexity of the gut microbiota. The gut microbiota is a central component of the host’s phenotype. The host’s intrinsic characteristics and diet both influence the composition and metabolic activity of the gut microbiota. Changes in the gut microbiota affect the processes involved in energy storage and influence gene expression in various tissues of the host, which contributes to the occurrence of metabolic disorders associated with obesity.

**Figure 1** The gut microbiota is a central component of the host’s phenotype. The host’s intrinsic characteristics and diet both influence the composition and metabolic activity of the gut microbiota. Changes in the gut microbiota affect the processes involved in energy storage and influence gene expression in various tissues of the host, which contributes to the occurrence of metabolic disorders associated with obesity.

**Table:**

<table>
<thead>
<tr>
<th>Host</th>
<th>Changes in phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic background</td>
<td>Fat mass development</td>
</tr>
<tr>
<td>Sex</td>
<td>Glucose tolerance</td>
</tr>
<tr>
<td>Age</td>
<td>Insulin sensitivity</td>
</tr>
<tr>
<td>Immune system</td>
<td>Inflammation</td>
</tr>
<tr>
<td>Gut motility</td>
<td>Steatosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diet</th>
<th>Changes in microbial metabolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-digestible carbohydrates</td>
<td>Saccharolytic activity</td>
</tr>
<tr>
<td>Fat</td>
<td>Production of bile acids</td>
</tr>
<tr>
<td>Prebiotics or probiotics</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Changes in composition (phylogenetic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>Phyla: Bacteroidetes and Firmicutes</td>
</tr>
<tr>
<td>Gastric bypass</td>
<td>Class: Mollicutes</td>
</tr>
<tr>
<td></td>
<td>Species or genera:</td>
</tr>
<tr>
<td></td>
<td>Bifidobacteria</td>
</tr>
<tr>
<td></td>
<td>Faecalibacterium prausnitzii</td>
</tr>
<tr>
<td></td>
<td>Lactobacilli</td>
</tr>
</tbody>
</table>

© 2011 Macmillan Publishers Limited. All rights reserved

www.nature.com/nrendo
commensal relationship between the gut microbiota and the host. Mutant mice that lack TLRs (or the signaling components downstream of TLRs, such as Myd88) have an altered microbial composition in the gut.\textsuperscript{25,26} Characteristics of the gut microbiota contribute to the host's phenotype (Figure 1). If an altered gut microbiota is transplanted into germ-free recipients, the functional characteristics of the donor microbiota can be transferred as well. Non-obese diabetic (NOD) mutant mice, which are prone to develop type 1 diabetes mellitus, were protected from the disease if Myd88 was ablated, and this protection could be transferred to germ-free recipients.\textsuperscript{25} The obesity trait was transmissible by transplanting the 'obese' microbiota of leptin-deficient ob/ob mice into germ-free mice,\textsuperscript{7} or by transplantation of a Western-diet-associated microbiome to germ-free mice, even if the recipient mice consumed a standard, low-fat, high-carbohydrate diet after transplantation.\textsuperscript{7} Furthermore, Tlr5-deficient mice develop obesity, inflammation and metabolic syndrome.\textsuperscript{26} This phenotype is also transferred upon transplantation of the gut microbiota.

Other factors
In the host's intestines, several factors prevent the overgrowth of the microbiota. These factors include physical mechanisms, such as the rapid movement of epithelial cells from the crypt to the villus, the peristaltic movement of the gut\textsuperscript{22} and a thick mucus layer produced by goblet cells that selectively limits the access of bacteria to the epithelium in the colon.\textsuperscript{23} The obesity trait was transmissible by transplanting the 'obese' microbiota of leptin-deficient ob/ob mice into germ-free mice,\textsuperscript{7} or by transplantation of a Western-diet-associated microbiome to germ-free mice, even if the recipient mice consumed a standard, low-fat, high-carbohydrate diet after transplantation.\textsuperscript{7} Furthermore, Tlr5-deficient mice develop obesity, inflammation and metabolic syndrome.\textsuperscript{26} This phenotype is also transferred upon transplantation of the gut microbiota.

Gut microbiota and fat storage
Compared with their germ-free counterparts, mice with gut microbiota have an increased capability to harvest energy from the gut.\textsuperscript{27} Metagenomic analyses of the microbiota performed in obese mice and humans revealed an increased capacity for the degradation (fermentation) of carbohydrates.\textsuperscript{44} This shift increases the amount of short-chain fatty acids (such as acetate, propionate, butyrate, and l-lactate) that can be used as metabolic substrates by the host to increase the harvest of energy. In addition to their role as energy substrates, short-chain fatty acids have been proposed to bind to specific G-protein-coupled receptors (GPR41 and GPR43, also called the free fatty acid receptors FFAR3 and FFAR2, respectively), which might promote nutrient absorption and/or adipose tissue mass development. Studies performed in Gpr41-deficient mice suggested that the activation of GPR41 by short-chain fatty acids is responsible for the release of the gut hormone PYY. This peptide has been shown to decrease the intestinal transit time, which indicates that it promotes the absorption of nutrients, mostly glucose.\textsuperscript{44} Moreover, Gpr43 is overexpressed in mice that are fed an obesogenic, high-fat diet,\textsuperscript{29} which contributes to an increase in adipocyte differentiation and inhibits lipolysis in the adipose tissue. Gpr43-deficient mice fed a high-carbohydrate, high-fat diet had a lower body mass and a higher lean mass compared with wild-type mice.\textsuperscript{30} The short-chain fatty acids produced by fermentation could then act in different ways: as energy substrates and/or as metabolic regulators.

However, the energy spared by fermentation is not sufficient to explain why mice with normal gut microbiota that were fed with a high-carbohydrate, high-fat diet developed more adipose tissue and exhibited a greater glucose intolerance than germ-free mice that were fed the same diet.\textsuperscript{20,31,32} Furthermore, the drastic changes in the gut microbiota's composition that occur after an antibiotic treatment can protect against obesity, glucose intolerance and the insulin resistance induced by a high-fat, carbohydrate-free diet.\textsuperscript{33}

The gut microbiota might affect obesity by additional mechanisms beyond energy harvest and the associated short-chain fatty acid production. In accordance with this hypothesis, the gut microbiota also influence the expression of host genes, namely of those that are expressed in the intestine, and control fatty acid absorption, oxidation and storage. One such target is the angiopoietin-related protein 4 (Angptl4), a potent lipoprotein lipase inhibitor.\textsuperscript{34} Angptl4 inhibits the uptake of fatty acids from circulating triglyceride-rich lipoproteins in white adipose and muscle tissues and promotes fatty acid oxidation, both in skeletal muscle cells and in adipocytes.\textsuperscript{32,33} The overexpression of Angptl4 in white adipose tissue also reduces fat mass.\textsuperscript{35} Conversely, germ-free, Angptl4-deficient mice exhibit increased lipoprotein lipase activity and adiposity compared with their wild-type counterparts.\textsuperscript{36} Interestingly, normal mice exhibit a reduced expression of Angptl4 in the small intestine compared with germ-free mice, which promotes adipose tissue development.\textsuperscript{36} These observations suggest that Angptl4 is a key host protein that is responsive to the gut's microbial environment and can modulate adiposity by controlling fatty acid uptake and metabolism in the tissues.

Colonization of germ-free mice with a typical environmental microbial population stimulates triglyceride synthesis and glycogenesis in the liver. These changes are attributable to a specific microbial family of the phylum Actinobacteria, namely Coriobacteriaceae.\textsuperscript{37} Interestingly, nuclear magnetic resonance spectroscopy of urinary and tissue samples showed changes in bile acid metabolism in the liver of colonized mice, which might contribute to the increase in dietary lipid absorption and the development of hepatic steatosis.\textsuperscript{37}

Gut microbiota and obesity
According to a new hypothesis, gut microbes have a role in the host's metabolic homeostasis.\textsuperscript{36,39} As type 2 diabetes mellitus and obesity are associated with low-grade inflammation and an altered composition of the gut microbiota, a bacterial compound might act as a triggering factor in the development of obesity, diabetes mellitus and inflammation induced by a high-fat diet. Several experiments indicated that this bacterial compound might be lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria.

Mice fed a high-fat diet exhibited enhanced levels of plasma LPS, a state described as metabolic endotoxemia.\textsuperscript{40} The elevated serum LPS level is unlikely to be explained
by an increased number of gram-negative bacteria in the gut of individuals with obesity, as such an increase has not been observed in mice nor humans. Associations between circulating LPS level, consumption of a high-fat diet and the presence of obesity and type 2 diabetes mellitus have been confirmed in humans. Erridge and coworkers found that a high-fat diet induces metabolic endotoxemia in healthy individuals. A link between energy intake (high-fat diet) and metabolic endotoxemia has also been described. Moreover, Creely and colleagues demonstrated that metabolic endotoxemia is a factor associated with the development of type 2 diabetes mellitus.

Associations between endotoxemia and serum levels of insulin and triglycerides and an inverse relationship between endotoxemia and serum HDL cholesterol level were confirmed in patients with type 2 diabetes mellitus and obesity. Furthermore, associations have been proposed between high-fat diet, metabolic endotoxemia and levels of inflammatory markers (TLRs and SOCS3) in mononuclear cells. Finally, metabolic endotoxemia is associated with systemic and adipose tissue inflammation in pregnant women with obesity. Altogether, these findings reinforce the hypothesis that fat intake and absorption, obesity and the development of metabolic endotoxemia are related.

Some of the mechanisms that are involved in the development of metabolic endotoxemia seem to be related to the fat content of the diet. Several investigators have shown that intraluminal fat increases intestinal LPS absorption through its incorporation into chylomicrons. Accordingly, the administration of lipase inhibitors reduces the severity of metabolic endotoxemia. A growing amount of evidence indicates that changes in the integrity of the intestinal barrier occur both in the proximal and the distal part of the gut, which can contribute to the entrance of LPS into the systemic circulation. Altered distribution and localization of two tight-junction proteins (ZO-1 and occludin) in the intestinal epithelium have been associated with an increased permeability of the intestinal wall in obese and diabetic rodents. Furthermore, glucagon-like peptide-2 (GLP-2), a gut peptide already known to be involved in the control of epithelial cell proliferation, was confirmed as a regulator of the expression and localization of tight-junction proteins and of the permeability of the intestinal wall in obese mice.

The intestinal endocannabinoid system is expressed differently in germ-free and normal mice and is over-activated in obese mice. The endocannabinoid system is composed of bioactive lipids (including anandamide) that bind to specific receptors (cannabinoid receptors 1 and 2 and peroxisome proliferator-activated receptors) and thereby influences energy homeostasis and immunity. Activation of the endocannabinoid system in ob/ob mice contributes to an increased permeability of the intestinal wall, an increased plasma level of LPS and systemic inflammation. A ‘crosstalk’ between the endocannabinoid system and the gut microbiota also participates in the regulation of adipogenesis directly by acting on the adipose tissue and indirectly by increasing plasma LPS levels. Although correlations have been found between changes in the gut microbiota composition and the elements controlling the gastrointestinal barrier function, such as GLP-2 and the endocannabinoid system, the direct involvement of specific gut microbes and/or of microbial metabolites in this control remains to be elucidated.

In humans, the contribution of changes in the integrity of the gut barrier to obesity and obesity-related inflammation remains to be confirmed. Brignardello and coworkers did not find any substantial difference in the permeability of the intestinal wall in the proximal gut in obese versus lean individuals. Further studies with a greater number of patients are needed to confirm the relationships between the permeability of the gut wall (in the proximal as well as the distal part of the gut), endotoxemia and the metabolic alterations in patients with obesity and type 2 diabetes mellitus.

Few studies have been aimed at finding correlations between the composition of the microbiota and the occurrence of inflammation and metabolic alterations in individuals with obesity. An interesting study showed that the number of Faecalibacterium prausnitzii decreases in patients with diabetes mellitus and is inversely correlated with inflammatory markers. The low-grade systemic inflammation that characterizes the obese phenotype is controlled by peptides that are produced in the gut. These peptides are influenced by the presence or absence of the gut microbiota. One such protein is the serum amyloid A3 protein (SAA3), which is the most abundant SAA isoform in both the adipose tissue and the colon. SAA3 is upregulated in the adipose tissue of mice fed a high-fat diet and might be a mediator of the chronic inflammation associated with insulin resistance in obesity. The gut microbiota is an important regulator of SAA3 expression. Expression of this peptide was substantially increased in the adipose tissue and colon (by 10-fold and sevenfold, respectively) of conventionalized mice—that is, mice colonized with a normal gut microbiota from a healthy wild-type mouse—compared with germ-free mice. Interestingly, SAA3 expression was mediated through the TLR–MyD88–NFκB signaling pathway.

Taken together, these findings suggest that the gut microbiota modulates the biological systems that regulate the availability of nutrients, energy storage, fat mass development and inflammation in the host, which are all components of the obese phenotype (Figure 2).

**Targeted changes in gut microbiota Effects of prebiotics**

In individuals with obesity, changes in the composition of the gut microbiota occur not only at the level of phyla but also at the level of genera or species. For example, a lower number of Bifidobacteria at birth has been associated with overweight later in childhood. Furthermore, overweight mothers give birth to neonates that have a decreased number of Bifidobacteria, which suggests that obeseogenic microbiota is an ‘inheritable’ trait. In adults, the number of Bifidobacteria (and of most groups
of *Firmicutes*) is slightly lower in individuals with obesity than in lean people.\(^1\) The number of these bacteria is also decreased in patients with type 2 diabetes mellitus compared with nondiabetic patients.\(^6\) These findings suggest that *Bifidobacteria* play a part in the development of obesity and its related comorbidities.

*Bifidobacteria* served as a model for the concept of prebiotics,\(^2\) which has been defined as “the selective stimulation of growth and/or activity(ies) of one or a limited number of microbial genus(era)/species in the gut microbiota that confer(s) health benefits to the host”.\(^2\)

Dietary fructans, which are present in various fruits and vegetables and added to food products, are used as an energy substrate by bacteria, including *Bifidobacterium spp.*, that express β-fructofuranosidase, which promotes their development in the gut. A remarkable increase has been observed in the number of *Bifidobacterium spp.* in mice with diet-induced or genetically determined obesity that were supplemented with inulin-type fructans.\(^2,6,41,53\)

Interestingly, the number of *Bifidobacteria* was inversely correlated with the development of fat mass, glucose intolerance, and LPS level.\(^4\) Moreover, the prebiotic approach prevented the overexpression of several host genes that are related to adiposity and inflammation, which was also associated with the colonization of germ-free mice with gut microbiota (Figure 2). Inulin-type fructans increased the number of endocrine L cells in the jejunum and in the colon of rodents, and promoted the production and release of the active forms of GLP-1 and GLP-2 in the portal vein.\(^6,44-67\)

Studies on experimental models of GLP-receptor invalidation indicate that GLP-1 participates in prebiotic-driven decreases in appetite, fat mass and hepatic insulin resistance,\(^6\) whereas GLP-2, as mentioned before, contributes to the reduced permeability of the intestinal wall and endotoxemia that are associated with obesity.\(^5\)

Interestingly, a 2-week treatment with inulin-type fructans (16 g per day) in healthy volunteers increased the post-prandial release of gut peptides (namely GLP-1 and gastric inhibitory peptide), to modify eating behavior (increased satiety and decreased calorie intake) and decrease post-prandial glycemia.\(^6,69\) In addition, inulin-type fructans also decreased the activity of the endocannabinoid system (by reducing the expression of cannabinoid receptor 1,
restoring the expression of anandamide-degrading enzyme and decreasing anadami levels in the intestinal and adipose tissues), a phenomenon that contributes to an improved barrier function of the gut and adipogenesis. Finally, inulin-type fructan prebiotics counteract the overexpression of GPR43 in the adipose tissue, which is related to a decreased rate of differentiation and a reduced adipocyte size.

Effects of probiotics

Another approach for promoting specific changes in the gut microbiota is the oral delivery of viable strains of bacteria (probiotics) that are then integrated into the gut ecosystem. Interestingly, germ-free mice that are monoconized with Lactobacillus paracasei in this way present an increased level of Angptl4. An increase in Angptl4 could also contribute to the decrease in fat mass observed in normal mice that are fed a high-fat diet supplemented with L. paracasei. The relevance of lactobacilli supplementation for the control of adiposity is a matter of debate. Some experts suggest that an increased number of intestinal Lactobacillus spp. is associated with an increased BMI and elevated level of blood glucose in healthy adults. The genus Lactobacillus comprises more than 90 species, and a more complete picture is necessary to discern the relevance of specific subspecies or strains in the control of adiposity.

In individuals with obesity, the administration of different strains of Lactobacillus has been shown to decrease fat mass and the risk of type 2 diabetes mellitus and insulin resistance (Table 1). Table 1 also summarizes the few available intervention studies in humans that examined the potential health effect of carbohydrates with prebiotic properties in patients with overweight, obesity or type 2 diabetes mellitus. Unfortunately, none of these studies report changes in the composition of the gut microbiota after probiotic or prebiotic treatment. Therefore, we cannot state at the moment that specific

Table 1 | Effects of probiotics or carbohydrates with prebiotic properties in patients with overweight or diabetes mellitus

<table>
<thead>
<tr>
<th>Microbiota</th>
<th>Study design</th>
<th>n</th>
<th>Duration</th>
<th>Treatment</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Probiotics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Lactobacillus acidophilus NCFM</em></td>
<td>Randomized, double-blind intervention</td>
<td>45 individuals with glucose intolerance and/or diabetes mellitus</td>
<td>4 weeks</td>
<td>Probiotic (1010 CFU/day) versus SiO2/lactose (placebo)</td>
<td>Systemic inflammation upon LPS challenge in both groups</td>
</tr>
<tr>
<td></td>
<td>Lactobacillus gasseri SBT2055</td>
<td>87 individuals with a BMI of 24.2–37.0 kg/m² and visceral adiposity</td>
<td>12 weeks</td>
<td>Fermented milk with probiotics (1011 CFU/day) or without probiotics (placebo)</td>
<td>Reduced body weight, BMI, waist and hip circumference, visceral and subcutaneous fat mass in the probiotic versus the placebo group</td>
</tr>
<tr>
<td><strong>Prebiotics (nondigestible carbohydrates)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inulin</td>
<td>Randomized, double-blind, placebo-controlled intervention</td>
<td>15 individuals with type 2 diabetes mellitus</td>
<td>5 weeks</td>
<td>Bread and muffins with 14% arabinobxylan (0% for placebo)</td>
<td>Reduced fasting glycemia, 1 post-OGTT glycemia and insulinemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No difference in blood lipid level, fat mass and blood pressure</td>
</tr>
<tr>
<td></td>
<td>Single-blind, controlled, cross-over intervention</td>
<td>11 individuals with impaired glucose tolerance</td>
<td>6 weeks</td>
<td>15g arabinobxylan supplied daily via bread and powder or isocaloric bread rolls without arabinoxylan (placebo)</td>
<td>Reduced fasting and post-LMCT glycemia and triglyceridemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reduced total post-LMCT ghrelin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No difference in leptin, adiponectin, insulin, resistin and FFA levels</td>
</tr>
<tr>
<td>Inulin-type fructans</td>
<td>Randomized, double-blind, placebo-controlled intervention</td>
<td>48 individuals with overweight or obesity</td>
<td>12 weeks</td>
<td>21 g per day oligofructose or maltodextrin (placebo)</td>
<td>Reduced body weight, caloric intake, GIP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No difference in fasting glucose, insulin, ghrelin, GLP-1, PYY and leptin levels</td>
</tr>
<tr>
<td></td>
<td>Randomized, double-blind, cross-over intervention</td>
<td>10 individuals with type 2 diabetes mellitus</td>
<td>4 weeks</td>
<td>20 g short-chain fructans or 20 g sucrose (placebo)</td>
<td>No difference in caloric intake, body weight, levels of glucose, insulin, HDL, LDL and total cholesterol, triglyceride, apolipoprotein A1 and B, lipoprotein(a), FFA, hepatic glucose production, insulin-stimulated glucose metabolism</td>
</tr>
<tr>
<td></td>
<td>Randomized, double-blind, cross-over intervention</td>
<td>7 overweight patients with nonalcoholic steatohepatitis</td>
<td>8 weeks</td>
<td>16 g per day oligofructose or maltodextrine (placebo)</td>
<td>No difference in aspartate aminotransferase and fasting insulin levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No difference in levels of triglycerides, fasting glucose and cholesterol</td>
</tr>
</tbody>
</table>

*Arabinobxylans are complex carbohydrates found in the endosperm and the aleurone layer and in pericarp tissues of cereals. Their fermentation is associated with proliferation of Bifidobacteria and Lactobacilli. Arabinobxylans represent a new class of prebiotics that have a prebiotic index comparable to that of well-established prebiotics. * Inulin-type fructans are well-established prebiotics that can selectively stimulate the growth of Bifidobacteria and, in some cases, Lactobacilli, which markedly changes the composition of the gut microbiota. Most of the potential health benefits associated with their prebiotic effects were discovered and demonstrated using the same food ingredients and/or supplements. Abbreviations: AUC, area under curve; CFU, colony-forming unit; GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide 1; LMCT, liquid meal challenge test; LPS, lipopolysaccharide; MTT, meal tolerance test; FFA, free fatty acids; OGTT, oral glucose tolerance test; PYY, peptide YY.

© 2011 Macmillan Publishers Limited. All rights reserved
types of bacteria per se are responsible for the improvement of metabolism in individuals with obesity who are treated with probiotic or prebiotic preparations.

Conclusions
Several potential mechanisms might allow gut microbes to interact with the host’s tissues and to regulate its energy metabolism. The increase in LPS levels, defined as metabolic endotoxemia, that occurs in individuals with obesity demonstrates that specific components of the gut microbes could trigger metabolic disorders. Experimental studies performed in animals clearly show that the gut microbiota also influences energy metabolism of the host, by regulating systems that have a crucial role in the control of nutrient absorption and metabolism, the integrity of the gut barrier, adipogenesis or hormonal status. These findings indicate that certain molecular targets (namely ANGPTL4, GPR43/41, GLP-1 and the intestinal endocannabinoid system) might be involved in the control of obesity and obesity-related disorders.

Numerous data have been published regarding differences in the composition of the gut microbiota in obese versus lean individuals, in animal models as well as in humans. At present, we cannot conclude that specific genera, classes or species of bacteria are always positively or negatively associated with the obese phenotype. In most cases, however, statistically significant relationships have been established between the presence and/or the amount of specific bacteria and the host phenotype. Integrative approaches using metabolomics and metagenomics should be performed to elucidate the metabolic interactions between the host and the gut microbes in individuals with obesity, and to assess the relevance of probiotic or prebiotic approaches in the control of obesity and obesity-related diseases in humans.

Review criteria
A PubMed search was performed by using the following key words (separately or combined): “gut microbiota”, “bacteria”, “obesity”, “adiposity”, “energy”, “metabolism”, “inflammation”, “prebiotic”, “probiotic”. Selected papers, including reviews, were published between 1990 and 2011 and chosen on the basis of their content (quality and novelty). The authors focused on specific molecular aspects of the interactions between the host and gut microbes, including endotoxemia. The final list of references was established by adding references suggested by the peer-reviewers.


Author contributions
All authors contributed equally to all aspects of the article.